Armen Margaryan, MD
Nephrology · Delray Beach, FLNPI 1134394067
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 67.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $5,480 and has fallen 73.5% since, to $1,451 in 2025. Among nephrology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $44.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Bayer$653
- Amgen$558
- Vifor Pharma, Inc.$487
- Otsuka America Pharmaceutical, Inc.$434
- Boehringer Ingelheim$278
- plus $1K from 14 others
What the payments were for
- Consulting fees$1752%
- Speaking & faculty fees$5,90053%
- Food & beverage$4,95945%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 81 | $7,501 |
| Bayer | 49 | $653 |
| Amgen(2 entities) | 20 | $558 |
| Vifor Pharma, Inc. | 14 | $487 |
| Otsuka America Pharmaceutical, Inc. | 25 | $434 |
| Boehringer Ingelheim | 12 | $278 |
| Mallinckrodt Hospital Products Inc. | 10 | $209 |
| Calliditas Therapeutics US Inc. | 7 | $182 |
| Novo Nordisk | 7 | $143 |
| Akebia Therapeutics Inc | 5 | $138 |
| Novartis | 4 | $99 |
| ANI Pharmaceuticals, Inc. | 3 | $89 |
| GSK | 4 | $81 |
| Renalytix AI, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $42 |
| Cormedix Inc. | 1 | $40 |
| Fresenius USA Marketing, Inc. | 2 | $36 |
| Nxstage Medical, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,079 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 324 | $351,078 |
| JardianceEmpagliflozin | 139 | $128,682 |
| KerendiaFinerenone | 86 | $113,709 |
| LokelmaSodium Zirconium Cyclosilicate | 66 | $75,179 |
| OzempicSemaglutide | 42 | $52,291 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $38,833 |
| MounjaroTirzepatide | 37 | $38,123 |
| SpsSodium Polystyrene Sulfon/Sorb | 44 | $8,584 |
| EntrestoSacubitril/Valsartan | 14 | $8,213 |
| Cinacalcet Hcl | 27 | $8,190 |
| Potassium Citrate ErPotassium Citrate | 38 | $4,925 |
| Irbesartan | 174 | $4,050 |
| Sevelamer Carbonate | 32 | $3,594 |
| Doxazosin Mesylate | 116 | $2,370 |
| Midodrine Hcl | 21 | $1,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $7,501 | $426,257390 claims |
| Boehringer IngelheimJardiance | $278 | $128,682139 claims |
| BayerKerendia | $653 | $113,70986 claims |
| Novo NordiskOzempic | $143 | $52,29142 claims |
| Lilly USA, LLCMounjaro | $42 | $38,12337 claims |
| NovartisEntresto | $99 | $8,21314 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $89 | $1,76835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.
Other nephrology in Delray Beach
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.